Swiss National Bank boosted its position in shares of Mylan NV (NASDAQ:MYL) by 16.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,701,042 shares of the company’s stock after purchasing an additional 238,200 shares during the quarter. Swiss National Bank’s holdings in Mylan were worth $61,476,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Analyst IMS Investment Management Services Ltd. purchased a new position in Mylan during the 1st quarter worth $117,000. First Mercantile Trust Co. purchased a new position in Mylan during the 2nd quarter worth $121,000. CENTRAL TRUST Co increased its holdings in Mylan by 1,057.8% during the 2nd quarter. CENTRAL TRUST Co now owns 5,210 shares of the company’s stock worth $188,000 after purchasing an additional 4,760 shares during the period. FTB Advisors Inc. purchased a new position in Mylan during the 2nd quarter worth $188,000. Finally, Piedmont Investment Advisors LLC purchased a new position in Mylan during the 2nd quarter worth $218,000. Institutional investors own 82.41% of the company’s stock.
Shares of NASDAQ:MYL opened at $38.69 on Monday. Mylan NV has a 12-month low of $29.53 and a 12-month high of $47.82. The firm has a market capitalization of $19.95 billion, a PE ratio of 8.48, a P/E/G ratio of 1.23 and a beta of 1.34. The company has a current ratio of 1.29, a quick ratio of 0.77 and a debt-to-equity ratio of 1.18.
Several research analysts have commented on the company. BidaskClub downgraded Mylan from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. Evercore ISI upgraded Mylan from an “in-line” rating to an “outperform” rating in a report on Friday. ValuEngine upgraded Mylan from a “sell” rating to a “hold” rating in a report on Wednesday, June 13th. Cantor Fitzgerald set a $41.00 price objective on Mylan and gave the stock a “hold” rating in a report on Friday, June 29th. Finally, Leerink Swann reduced their price objective on Mylan from $53.00 to $47.00 and set an “outperform” rating on the stock in a report on Thursday, August 9th. Seven research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $47.37.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.